B7 homolog 3 in pancreatic cancer

doi:10.3748/wjg.v30.i31.3654

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 31

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1807)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

HTML

1075

Figures (1-1)

103

Tables (1-2)

113

Sum=1326

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

151

Download

154

Sum=305

Publishing Process of This Article

Item

Count

Browse

Download

Sum=107

Aug 21, 2024 (publication date) through Nov 12, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Aug 21, 2024; 30(31): 3654-3667
Published online Aug 21, 2024. doi: 10.3748/wjg.v30.i31.3654

Table 2 Clinical studies involving B7 homolog 3-targeting agents in pancreatic cancer

Ref.	Agent/drug	Route of administration	Study participants	Status
NCT05293496, phase I[106]	Vobramitamab duocarmazine¹ in combination with lorigerlimab²	Intravenous	Patients with relapsed or refractory, unresectable, locally advanced, or metastatic solid tumors including PC	Recruiting
NCT06330064, phase II[110]	I-DXD³	Intravenous	Patients with recurrent or metastatic solid tumors, including PDAC	Recruiting
NCT02628535, phase I[113]	Orlotamab⁴	Intravenous	Patients with unresectable or metastatic B7-H3-expressing neoplasms including PC	Terminated
NCT05143151, phase I/phase II[117]	CD276 CAR T cells	Intravenous	Adult patients with refractory PC	Recruiting
NCT06158139, phase I[118]	Ic9-CAR.B7-H3 T cells	Intravenous	Adult patients with refractory PDAC	Not yet recruiting

¹Also known as MGC018, an antibody-drug conjugate comprised of a humanized anti-B7 homolog 3 (B7-H3) monoclonal antibody (mAb) conjugated via a cleavable linker to the prodrug seco-duocarmycin hydroxybenzamide azaindole.

²Bispecific dual-affinity re-targeting (DART) molecule that targets both cytotoxic T lymphocyte-associated protein 4 and programmed cell death protein 1.

³B7-H3–directed antibody-drug conjugate consisting of anti-B7-H3 IgG1 mAb (MABX-9001a) and a payload, a potent DNA topoisomerase I inhibitor.

⁴CD3xB7-H3 DART protein also known as MGD009.

CAR: Chimeric antigen receptor; I-DXD: Ifinatamab deruxtecan; PC: Pancreatic cancer; PDAC: Pancreatic ductal adenocarcinoma; B7-H3: B7 homolog 3.

Citation: Perovic D, Dusanovic Pjevic M, Perovic V, Grk M, Rasic M, Milickovic M, Mijovic T, Rasic P. B7 homolog 3 in pancreatic cancer. World J Gastroenterol 2024; 30(31): 3654-3667
URL: https://www.wjgnet.com/1007-9327/full/v30/i31/3654.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i31.3654